Literature DB >> 33174415

Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.

Helen M Deeks1,2,3, Rebecca K Walters1,2,3, Jonathan Barnoud1,2, David R Glowacki1,2,3, Adrian J Mulholland2.   

Abstract

The main protease (Mpro) of the SARS-CoV-2 virus is one focus of drug development efforts for COVID-19. Here, we show that interactive molecular dynamics in virtual reality (iMD-VR) is a useful and effective tool for creating Mpro complexes. We make these tools and models freely available. iMD-VR provides an immersive environment in which users can interact with MD simulations and so build protein complexes in a physically rigorous and flexible way. Recently, we have demonstrated that iMD-VR is an effective method for interactive, flexible docking of small molecule drugs into their protein targets (Deeks et al. PLoS One 2020, 15, e0228461). Here, we apply this approach to both an Mpro inhibitor and an oligopeptide substrate, using experimentally determined crystal structures. For the oligopeptide, we test against a crystallographic structure of the original SARS Mpro. Docking with iMD-VR gives models in agreement with experimentally observed (crystal) structures. The docked structures are also tested in MD simulations and found to be stable. Different protocols for iMD-VR docking are explored, e.g., with and without restraints on protein backbone, and we provide recommendations for its use. We find that it is important for the user to focus on forming binding interactions, such as hydrogen bonds, and not to rely on using simple metrics (such as RMSD), in order to create realistic, stable complexes. We also test the use of apo (uncomplexed) crystal structures for docking and find that they can give good results. This is because of the flexibility and dynamic response allowed by the physically rigorous, atomically detailed simulation approach of iMD-VR. We make our models (and interactive simulations) freely available. The software framework that we use, Narupa, is open source, and uses commodity VR hardware, so these tools are readily accessible to the wider research community working on Mpro (and other COVID-19 targets). These should be widely useful in drug development, in education applications, e.g., on viral enzyme structure and function, and in scientific communication more generally.

Entities:  

Year:  2020        PMID: 33174415      PMCID: PMC7671099          DOI: 10.1021/acs.jcim.0c01030

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  48 in total

1.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

2.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

3.  Conservation of substrate specificities among coronavirus main proteases.

Authors:  Annette Hegyi; John Ziebuhr
Journal:  J Gen Virol       Date:  2002-03       Impact factor: 3.891

4.  Crowdsourcing drug discovery for pandemics.

Authors:  John Chodera; Alpha A Lee; Nir London; Frank von Delft
Journal:  Nat Chem       Date:  2020-07       Impact factor: 24.427

5.  Methods of protein structure comparison.

Authors:  Irina Kufareva; Ruben Abagyan
Journal:  Methods Mol Biol       Date:  2012

6.  Modelling proteins' hidden conformations to predict antibiotic resistance.

Authors:  Kathryn M Hart; Chris M W Ho; Supratik Dutta; Michael L Gross; Gregory R Bowman
Journal:  Nat Commun       Date:  2016-10-06       Impact factor: 14.919

7.  ProteinVR: Web-based molecular visualization in virtual reality.

Authors:  Kevin C Cassidy; Jan Šefčík; Yogindra Raghav; Alexander Chang; Jacob D Durrant
Journal:  PLoS Comput Biol       Date:  2020-03-31       Impact factor: 4.475

8.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.

Authors:  Yu Wai Chen; Chin-Pang Bennu Yiu; Kwok-Yin Wong
Journal:  F1000Res       Date:  2020-02-21

9.  Processing of the SARS-CoV pp1a/ab nsp7-10 region.

Authors:  Boris Krichel; Sven Falke; Rolf Hilgenfeld; Lars Redecke; Charlotte Uetrecht
Journal:  Biochem J       Date:  2020-03-13       Impact factor: 3.857

Review 10.  An immersive journey to the molecular structure of SARS-CoV-2: Virtual reality in COVID-19.

Authors:  Martín Calvelo; Ángel Piñeiro; Rebeca Garcia-Fandino
Journal:  Comput Struct Biotechnol J       Date:  2020-09-18       Impact factor: 7.271

View more
  6 in total

1.  Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.

Authors:  Himanshu Rai; Atanu Barik; Yash Pal Singh; Akhil Suresh; Lovejit Singh; Gourav Singh; Usha Yogendra Nayak; Vikash Kumar Dubey; Gyan Modi
Journal:  Mol Divers       Date:  2021-02-13       Impact factor: 3.364

Review 2.  Open-Source Browser-Based Tools for Structure-Based Computer-Aided Drug Discovery.

Authors:  Ann Wang; Jacob D Durrant
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

3.  A virtual reality classroom to teach and explore crystal solid state structures.

Authors:  Erica Stella; Isabella Agosti; Nicoletta Di Blas; Marco Finazzi; Pier Luca Lanzi; Daniele Loiacono
Journal:  Multimed Tools Appl       Date:  2022-08-11       Impact factor: 2.577

4.  Accelerating COVID-19 Research Using Molecular Dynamics Simulation.

Authors:  Aditya K Padhi; Soumya Lipsa Rath; Timir Tripathi
Journal:  J Phys Chem B       Date:  2021-07-28       Impact factor: 2.991

Review 5.  Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition.

Authors:  Guillem Macip; Pol Garcia-Segura; Júlia Mestres-Truyol; Bryan Saldivar-Espinoza; María José Ojeda-Montes; Aleix Gimeno; Adrià Cereto-Massagué; Santiago Garcia-Vallvé; Gerard Pujadas
Journal:  Med Res Rev       Date:  2021-10-26       Impact factor: 12.388

6.  Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.

Authors:  Merve Yuce; Erdem Cicek; Tugce Inan; Aslihan Basak Dag; Ozge Kurkcuoglu; Fethiye Aylin Sungur
Journal:  Proteins       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.